Veeva price target raised to $245 from $240 at Barclays

Barclays raised the firm’s price target on Veeva to $245 from $240 and keeps an Overweight rating on the shares. The company reported better Q4 billings with two more top 20 pharma’s adopting EDC, and one more top 20 committing to Vault CRM, the analyst tells investors in a research note. The firm says the fiscal fiscal 2025 guidance trim is entirely services as Veeva is investing in customers to lessen the burden of migrating to Vault CRM.